Last reviewed · How we verify
PITAVASTATIN MAGNESIUM
Pitavastatin inhibits HMG-CoA reductase, reducing cholesterol synthesis and increasing LDL uptake by the liver.
At a glance
| Generic name | PITAVASTATIN MAGNESIUM |
|---|---|
| Drug class | HMG-CoA Reductase Inhibitor [EPC] |
| Target | 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2017 |
Mechanism of action
Pitavastatin works by blocking the enzyme HMG-CoA reductase, which is crucial for cholesterol production. This leads to increased LDL receptor expression and more LDL being removed from the bloodstream, lowering cholesterol levels.
Approved indications
Common side effects
- Myalgia
- Constipation
- Diarrhea
- Back pain
- Pain in extremity
- Arthralgia
- Headache
- Influenza
- Nasopharyngitis
- Rash
- Pruritus
- Urticaria
Serious adverse events
- Elevated creatine phosphokinase
- Myalgia (discontinuation)
- Hepatitis
- Jaundice
- Rhabdomyolysis
- Muscle pain/weakness
- Elevated transaminases
- Elevated alkaline phosphatase
- Elevated bilirubin
- Elevated glucose
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PITAVASTATIN MAGNESIUM CI brief — competitive landscape report
- PITAVASTATIN MAGNESIUM updates RSS · CI watch RSS